becoming more enlightened, and in this life of continuos, learning cycle....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kannalife is doing this also.announced in April-.The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (“LEA”), the International Nomenclature of Cosmetic Ingredient (INCI) assigned name for the Company’s patented monotherapeutic compound KLS-13022.
In pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFa, Il-1ß, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and currently among the targets believed to be creating the cytokine storm in SARS-CoA-2 (“COVID-19”)..https://www.kannalife.com/kannalife-inc-receives-notice-of-allowance-from-uspto-for-trademark-of-atopidine/
Calm before the good storm, you betcha it is....cheers ...
MJNA and its APIS BULL Will reign once again... The shinning will return to its glory days with The very first publicly traded CBD company which will be first in line and one of a kind once again. best wishes..
IF ONLY YOU PEEPS KNEW HOW IMPORTANT THIS IS -KANNALIFE, INC. RECEIVES NOTICE OF ALLOWANCE FROM USPTO FOR TRADEMARK OF ATOPIDINE™
DOYLESTOWN, Pa., April 01, 2020 (GLOBE NEWSWIRE) — Kannalife, Inc. (“Kannalife” or the “Company”) (OTCQB: KLFE), a biopharmaceutical medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its trademark application for the mark, “Atopidine”.
The Company chose Atopidine™ as the trademark for Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine (“LEA”), the International Nomenclature of Cosmetic Ingredient (INCI) assigned name for the Company’s patented monotherapeutic compound KLS-13022.
In pre-clinical testing, Atopidine™ was shown to decrease inflammatory cytokine (TNFa, Il-1ß, CXCL5 and IL-8) levels at concentrations 50 times less than toxic levels. Atopidine™ was effective in an in vitro photoaging experiment with anti-inflammatory action based on IL-6 inhibition against UVA irradiation in cultured human dermal fibroblasts cells. IL-6 is a cytokine (an immune system signaling molecule) that has been shown to promote inflammation and currently among the targets believed to be creating the cytokine storm in SARS-CoA-2 (“COVID-19”).
The Company is hoping to have Atopidine™ as a finished product by the end of 2020 for commercial use as an emollient to address a number of skin care and personal care needs.
Due to rising concerns regarding skin problems, various synthetic and natural products are driving the skin care industry. According to a recent report, the global skin care products market size is projected to reach $183.03 billion USD by 2025.1
“We are currently testing the anti-inflammatory and antioxidant potential of our patented compound Atopidine™ versus Betamethasone, a well-known corticosteroid and cannabidiol (CBD). When these studies are completed, we believe we will have a superior compound in treating keratinocyte-derived cytokine related skin disorders. After that, we would be really interested to see how Atopidine™ works with and compares to Kevzara (sarilumab) from Sanofi-Regeneron and Roche’s Actemra (tocilizumab), both IL-6 human monoclonal antibodies used in treating severe rheumatoid arthritis,” said Dean Petkanas, CEO of Kannalife.
About KLS-13022
KLS-13022 is a proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of skin care, anti-inflammatory, antioxidant, and personal care needs. KLS-13022 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It’s safety and efficacy have not been confirmed by FDA-approved research.
MJNA facebook page has never ever been down- its been down for several days which also tells me a revamping is in the works. we know what's about to happen. read in-between the lines of every press release this year..
its says JUNE29TH earning release - everything in the future can be subject to change tho. its changed before but feeling confident this time. I am not an insider but have been doing this since 1999.
MJNA A MAJOR PARTICIPANT-Assessment of COVID-19's Effect on Medical Marijuana Market 2020-2024 | Production Of Medical Marijuana to Augment Growth | Technavio
Business Wire Business WireJune 22, 2020
The market is highly fragmented, and the degree of fragmentation will accelerate during the forecast period. Aphria Inc., Aurora Cannabis Inc., Cannabis Sativa Inc., Canopy Growth Corp., Cronos Group Inc., GW Pharmaceuticals Plc, mCig Inc., Medical Marijuana Inc., United Cannabis Corp., and Vivo Cannabis Inc. are some of the major market participants.
https://finance.yahoo.com/news/assessment-covid-19s-effect-medical-153000325.html
Cannabidiol Market Huge Growth, Latest Trends And Demand Forecasts By 2026|Pure CBD Factory, Exactus, Inc., ENDOCA, Medical Marijuana, Inc
Post author
By Data Bridge Market Research
Post date
June 23, 2020 https://jewishlifenews.com/uncategorized/cannabidiol-market-huge-growth-latest-trends-and-demand-forecasts-by-2026pure-cbd-factory-exactus-inc-endoca-medical-marijuana-inc/
I believe something could be happening g to change this. My gut feeling says the floodgates will be commensing very soon.
that would sky rocket this, if it happened... its for sure a threshold to cross to resume momentum
More than one can play the bid and ask game here at MJNA - not just corrupt brokers manipulating MJNA for illegal gaming - I see what they do- I will play with it also- I am not mr small purchase guy or small timer stock player. I know what I am doing and I see what they are doing. Others do to- someone has been very successful in making this stock unknown and silent but it will not be deadly like some have claimed.It will rise above to uncharted territory. They brought it down and I just bought more and more. I was one of the only ones buying here at .0011-.013- I did sell all of it above .03- I am not careless and this will go even higher next time. I have been buying again....... life can be good to the patient and the wise. good luck my brothers and sisters..
GOOD LUCK TRYING TO BUY A LARGE AMOUNT AT THIS PRICE- one has to slowly sneak their way in so no one knows one is buying a TON OF SHARES... and again best of luck...
that's why its called a quite period for that aspect- I said enough in my last post regarding this about MJNA. its not a disagreement bud -dy
this is good education for some who don't know why this happens
A quiet period is the period of time when company insiders are required to limit certain business-related communication with the public. During this time, communication is monitored and enforced by the US Securities and Exchange Commission (SEC). The purpose of the quiet period is to preserve objectivity and avoid the appearance of a company providing insider information to select investors.
the lid is about to blow here very soon....
FINANCIALS YOU SAY? Market Value? yes this will be good and is 100% obvious this is the holdup on financials. usually they are pretty on time with their unaudited non transparent earnings- but third time a charm for next week? At this point they clearly are not a fake company with the awards and people who constantly come on board with a background that has a paper trail. The cancer clinical trials and recent patent on various things is real. The award Kannaway received is real. Their products are in stores. One can order it online. With AXIM and KLFE on the OTCBB those two together have a market value of 132 million. MJNA with other facets such as hempmedspx and Kannaway, a 63 milling street value for Medical Marijuana inc is simply improper and valued not in accordance with market value. We know the reasons...... pink sheets and probably hundreds of millions or even billions in short sales.
https://www.kannaway.com. $88.4 million
https://aximbiotech.com. $44.9 million
$132 million
BASED ON ABOVE VALUE WE WILL BE CONSERVATIVE- NOTE THESE TWO BELOW ARE A MAJORITY OF SALES
https://hempmedspx.com - 40 MILLION
https://www.kannalife.com. 40 MILLION
$80 million
PARENT COMPANY-
https://www.medicalmarijuanainc.com 63 MILLION
WE CAN SEE HOW MUCH THE BASELINE VALUE IS VERY MUCH NOT IN TOUCH WITH REALITY-
When this blows the roof will blow with it as it will not contain the share price increase- it will go through the roof all four together would be$ 210 million dollars for market value on MJNA minimum without an audit- with an audit most likely 5 times that as the very first public company in this arena
MJNA- ALPINE SECURITIES-Alpine violated FINRA Rule 2150 for converting customer funds, FINRA Rule 2150 for misusing customer assets, FINRA Rule 2010 for unauthorized trading, FINRA Rule 2121 for implementing unfair prices and commissions, FINRA Rule 2122 for unreasonable and discriminatory fees, and FINRA Rule 4110(c) for unauthorized capital withdrawals.
FINRA Department of Enforcement is requesting that the Panel make findings of fact and conclusions that Alpine committed these violations and order the firm to disgorge ill-gotten gains and/or make full restitution, with interest.
IF YOU CALL THEM YOU WILL GET TO TALK TO NOBODY AS ITS ON A LOOP- THEY ARE GOING BALLS OUT HERE ON MJNA AND SOON THEY WILL HAVE THEIR SECURITES LICENSE REVOKED- PEOPLE ARE ONTO ALPINE AS THEY SELL SHARES THEY NEVER HAVE- THEY ARE UNDER INVESTIGATION BY THE SEC AND FINRA department of enforcement- they can only sell shares- they can not open n ew positions for clients- they can not buy them so they are shorting with no intention of ever covering a stock the prey upon- I am making my calls and I suggest every shareholder to the same- the are doing the same here with unauthorized trading of borrowed shares. I have been watching this broker with MJNA trading and they are 100% guilty.
this concerns MJNA- ALPINE IS KNOWN SHORTER AND SCAMMER OF THE LITTLE GUYS SHARES for their own benifit- FINRA Complaint Alleges Salt Lake City Broker-Dealer Alpine Securities Corporation Scams Millions from Customers in the Face of Multi-Million Dollar Fine for SEC Violations
WEDNESDAY, AUGUST 14, 2019
Alpine Securities Corporation (Alpine), a broker-dealer based in Salt Lake City, Utah, was recently named respondent in a Complaint brought forth by the Financial Industry Regulatory Authority (FINRA) Office of Hearing Officers for allegedly converting and misusing customers’ securities, including implementing a series of exorbitant and arbitrary fees.
Alpine has been a FINRA member firm since May 1984 as a self-clearing broker-dealer that carries accounts for retail customers, who primarily hold over-the-counter stocks, and provides clearing services for introducing broker-dealers. John Hurry, who owns Scottsdale Capital Advisors Corp., a retail and institutional broker-dealer in Scottsdale, Arizona, acquired Alpine in 2011. In July 2018, Hurry was barred from associating with FINRA member firms in any capacity following its finding that he had created a broker-dealer overseas to evade federal securities laws in the Scottsdale office.
In December 2018, the court granted an SEC motion for summary judgment, concluding that Alpine had failed to file thousands of suspicious activity reports (SARs) and had filed thousands of other SARs with deficient information. The SEC filed a Motion for Remedies requesting that the court impose a $22 million fine against Alpine.
Now, FINRA alleges that, with the prospect of this multi-million dollar SEC fine and in the face of mounting financial struggles, Alpine instituted a $5,000 monthly account fee, which represented an increase of approximately 60,000% from the firm’s prior $100 annual account fee. Alpine then used these fees to convert customer funds. Alpine also pressured its customers into re-certificating their shares, applying a 100% or 200% markup to the DTC certificate withdrawal fee, and charged them an “illiquidity and volatility fee” through which the firm collected at least $1 million. To satisfy the significant debits the customers’ incurred in their accounts, Alpine told them that it would liquidate their securities or transfer them to proprietary Alpine accounts. In June 2019 alone, Alpine transferred over $950,000 in customer securities to these proprietary accounts.
FINRA further alleges that in early 2019, Alpine deemed any customer securities valued at $1,500 or less to be “worthless,” which it claimed entitled the securities to be purchase by Alpine for one penny per position. According to the Complaint, Alpine purchased or moved nearly $910,000 of these “worthless” customer securities, thus converting millions of shares of securities from its customers for its own benefit and only informed the customers of this activity after the fact. Alpine allegedly backdated a letter to customers and mailed it to the customers a full ten days after taking their securities without their knowledge or authorization. When customers received the letter, many attempted to contact the firm, but Alpine had closed its office, limited access to customers’ accounts on its web portal, and only provided a generic email address for customer contact, though Alpine was largely unresponsive to the customers’ questions.
FINRA also alleges in the Complaint that Alpine has been looting the firm since early 2019. Specifically, Alpine effected six capital withdrawals totaling approximately $2.8 million by claiming to make expense payments to affiliates. First, Alpine amended its pre-existing loan agreement with its affiliate lender, Alpine Securities Holding Corporation (Alpine Holding), to dramatically increase its payments for its line of credit. Then Alpine paid its affiliated landlord, SCAP 9 LLC (SCAP) over $600,000 in response to SCAP’s purported request for payment of “common area maintenance” charges, in addition to the monthly rent and insurance coverage.
Based on the foregoing, Alpine violated FINRA Rule 2150 for converting customer funds, FINRA Rule 2150 for misusing customer assets, FINRA Rule 2010 for unauthorized trading, FINRA Rule 2121 for implementing unfair prices and commissions, FINRA Rule 2122 for unreasonable and discriminatory fees, and FINRA Rule 4110(c) for unauthorized capital withdrawals.
FINRA Department of Enforcement is requesting that the Panel make findings of fact and conclusions that Alpine committed these violations and order the firm to disgorge ill-gotten gains and/or make full restitution, with interest.
SEC IS BEIING INFORMED ON WHAT ALPINE IS DOING HERE WITH MJNA
HERE IS WHO TO CALL AND COMPLAIN ABOUT WHAT THEY ARE DOING TO MJNA-
: Jason T. Albin
Jason Albin is an Attorney and Partner at ChapmanAlbin, the investor rights law firm. He has represented hundreds of investors who have lost money due to broker misconduct, unsuitable investment advice and fraud.? Jason also represents individuals in “whistleblower” suits filed against unscrupulous companies that try to defraud the US federal and state governments.
buying a bit today... to add to the pot....
hard fills gang
still too low for all the companies they have under their belt...it rings true and will make it so.Should be 500 million minimum
LETS GO GREEN MJNA....
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today it has expanded its research division through the establishment of a state-of-the-art laboratory in the biotechnology industry hub of San Diego, Calif. Additionally, respected scientist Dr. Sergei Svarovsky will lead the oncology-focused research team as the Chief Scientific Officer and a founder of its subsidiary, Sapphire Biotech, Inc. (“Sapphire”).
“With our recent acquisition of Sapphire, AXIM has pivoted into becoming an exciting new oncology-focused company. We look forward to moving our talented research team into this new fully outfitted research lab and support them in continuing to make important breakthroughs in oncology,” said AXIM® Biotech CEO John W. Huemoeller II. “Dr. Svarovsky has already led our team to make several landmark discoveries in our research since taking on his position and he shows great potential for discovering and patenting many more industry-leading innovations.”
AXIM’s new research laboratory sits adjacent to many of the world’s largest biotechnology companies. This location as well as the density of biotechnology companies in the area grant the Company the ability to increase the rapid tempo of its research due to easy access to nearby analytical services and vital chemistry and biology equipment.
The laboratory is fully equipped for all research to be done in-house by AXIM’s research team. The available equipment allows for the integration of synthetic organic chemistry, bioconjugations, assays and molecular biology operations.
To oversee this new lab and lead Sapphire’s research and product development efforts, Dr. Sergei Svarovsky has been appointed as Chief Scientific Officer. Dr. Svarovsky holds a Master of Science in Physical Chemistry from Novosibirsk State University, a Doctor of Philosophy in Physical Organic Chemistry and a Master of Business Administration from West Virginia University. He has extensive experience with innovative cancer drug design and development and medical diagnostics, including developing a wide range of biological assays for existing and novel instrumentation platforms for many well-known biotech companies. As a Research Fellow at the National Institute of Health’s (NIH) National Cancer Institute, Dr. Svarovsky’s novel innovations earned him the prestigious NIH Fellow Award for Research Excellence (FARE).
“I am passionate about Sapphire’s mission to reinvent global cancer care and agree that early detection is the best way to help reduce the number of people diagnosed with advanced stages of cancer each year,” said Dr. Sergei Svarovsky, Chief Scientific Officer of Sapphire Biotech. “Sapphire’s research team is incredibly talented and I look forward to using my diverse background as a scientist, educator, and product developer to help them achieve our goals.”
For more information about AXIM, please visit www.aximbiotech.com.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company developing diagnostic tests for the early detection of cancer, proprietary small molecules drugs not only to treat cancer but also to block metastasis and developing novel antibodies for therapeutic and diagnostic uses. AXIM is also developing new cannabinoid molecules for oncological therapeutics.
Currently, Sapphire Biotech, Inc.’s diagnostic tool is being used to study the company's enzyme biomarker to detect pancreatic cancer earlier than circulating tumor cells. For more information, please visit www.AXIMBiotech.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM® Biotechnologies, Inc. to be materially different from the statements made herein.
LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.com
Corporate Contact Info:
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-999-0920
Investor Relations Contact:
investors@aximbiotech.com
888-759-0844
"Dedicated to Changing Lives Through Research
Sapphire Biotech has identified a unique enzyme, Quiescin Sulfhydryl Oxidase 1 (QSOX1), which is elevated in cancer patients and can be detected earlier than circulating tumor cells. The company’s development of QSOX1 as a unique cancer biomarker has led it to important discoveries based on testing hundreds of human samples. Sapphire’s lead compound has been tested in animal studies has shown to significantly reduce tumors by two-thirds in under 20 days". https://sapphirebiotech.com
picked up more at .027
not sure what time - but it says earnings announcements for may 29th
Loading more -Hard fills- earrings TMRW-Hold tight its going to be amazing as it goes to new 52 week high
This may be the biggest mover of the year.... which in itself will make headlines.
This is so clear the financials will be filled this week(or soon).Its says this Friday. I have a great sense of awarenesses they are going to uplist once they are made aware to the public they indeed are so freakin real its like hitting the lottery. Look at all the awards and everything they do. They have more news releases than all the other pot stocks combined. When the bigger news happens and all the little hobbits jump in....... OMG the old days are back gang.. its indicative of the current ballistic moves.
a few sells and its quick on the spread back up on the ask- insiders and traders buying and holding- this hasn't even broke the ranks of mainstream traders and momentum players. This bodes really really well folks. be patient its coming
Smart money acquiring and holding for rocket launch- this is a move but not what is in store as it will be huge from the .02's so anyone holding will be simply amazed that dreams do come true. More amazement than its current performance. We are hitting support when needed. and Buying When needing to.
several times when I go to buy a bunch the price jumps up as soon as my order is in. This is indicative that this wants to go much much higher. investors and traders know what's up with this one...
MJNA WILL Double- Quadruple this WEEK!! eom
yes I believe itt will- its a hard fill today- when earning finally hits I have a huge feeling this goes apechit ballistic...towards the 10 cents arena
I REALLY BELIEVE DOUBLE OR TRIPLE EVEN FROM THE .02'S- SO EASY TO SEE-HOLD ON BROTHERS AND SISTERS. THE VOLUME IS INDICATIVE
WHY WOULD THEY MENTION IT NOW THEY ALREADY MENTIONED THEY HIRED TOP NOTCH FIRM. IT WILL HAPPEN WHEN IT HAPPENS BECAUSE THEY WONT SAY AUDIT ON FRIDAY OR ANY OTHER TIME. IT WILL JUST HAPPEN DO TO GUIDELINES MY FRIENDS
THEY HIRED AUDIT TEAM IN JANUARY FOR A REASON- THIS COMPANY HAS MORE GOING ON THAN NUMEROUS OTHER CANNABIS COMPANIES VALUED FROM 500 MILLION TO A BILLION THAT ARE SO ON THE VERGE OF BK. THIS HAS MONEY IN THE BANK HAS MORE AWARDS THAN ANY OTHER CANNABIS COMPANY LISTED ON THE EXCHANGES
I AGREE- PLUS MJNA HAS TWO OTHER LISTED COMPANIES VALUED AT 45 MILLION EACH.AND THEN HEMPMEDS WHICH IS 45 MILLION- THOSE THREE TOGETHER MAKE MJNA SO VALUABLE-LIKE 4-5 TIMES CURENT VALUE(minimum)
LOOKING GOOD HERE-MJNA HIRED TOP NOTCH FIRM THAT DEALS WITH SEC COMPLIANCE AUDITS AND MERGERS OR COMPANY SALE